QIAGEN Sample & Assay Technologies From Discovery to Patient

Transcription

1 QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7-

2 Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations for certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC). Our Future will have a major impact on Life Sciences research Pharmaceutical drug development Applied Markets In-Vitro Diagnostics Our role and goals are well defined We have a great starting position Great opportunities

3 QIAGEN s Leadership Formula 1. Focus Bundle strengths Lead in terms of resources Leverage focus 2. Lead Constant race 3. Take Leadership Global Act local, leverage global resources Global matrix QIAGEN Full Circle One Core Focus Academic Research Molecular Diagnostics Sample Assay Pharma/Clinical Applied Markets From Invention to Application to Patients Play Central Role

4 QIAGEN Full Circle One Core Focus Academic Research Molecular Diagnostics Sample Assay Pharma/Clinical Applied Markets QIAGEN Full Circle One Core Focus Academic Research Molecular Diagnostics Sample Assay Pharma/Clinical Applied Markets

5 QIAGEN Full Circle One Core Focus Academic Research Molecular Diagnostics Sample Assay Pharma/Clinical Applied Markets From Invention to Application to Patients Play Central Role Academic Research Molecular Diagnostics Sample Assay Pharma/Clinical Applied Markets

6 QIAGEN Full Circle One Core Focus Our current capabilities provide the basis for Molecular diagnostics: leadership Pharma: hotwiring clinical development and MDx Applied Markets: dissemination of molecular biology Academia: a close relationship with innovation.and all without loss of focus as the core capabilities stay the same. Leadership in All Market Segments in our Core Academia Applied Testing Pharma Molecular Diagnostics Market leader Market leader Market leader Market leader SAMPLE ASSAY

7 Leading Position Broad Footprint OEM >20 relationships Sample Transplantation Leading SSP Franchise New: sequence-based ~$400 Million HPV Franchise Real-time PCR assays 120 assays RUO 40 with regulatory approval Market Leadership in MDx Molecular Diagnostic Landscape (1) Sales in US$ millions 450 ~ Leading Market Positions Largest infectious disease assay portfolio Largest R&D budget in molecular technologies Largest sales & marketing force Extensive IP and technology portfolio No. 2 in PCR technology in MDx No. 1 in HPV testing No. 1 in automated sample processing No. 1 in manual sample preparation No. 1 in PCR/SSP HLA testing (#3 overall) 0 QIAGEN Roche MDx Genprobe Abbott (1) Excluding Viral Load and Blood banking business Bayer Cepheid Third Wave

8 QIAGEN With Record Sales and Double Digit Growth CAGR = 20% E (1) (1) Analyst estimates QIAGEN With Record Sales and Double Digit Growth E (1) (1) Refer to Company s guidance CAGR = 20% $

9 QIAGEN s Revenue Distribution By Product Groups Consumable growth increased Increasing trend Innovation-driven Consumables Sample technologies Assay technologies Instrumentation Very strong performance 90% Great pipeline QIAcube 10% Instruments BR 8000 Universal and MDx Selling Solutions QIAGEN s Revenue Distribution By Geographic Regions Globalization continues 2007: Turkey, Spain, Brazil, Luxemburg, Hong Kong 2008: incl. Eastern Europe and Latin America Asia 9% 13% RoW 3% of sales Global rollout of Women s Health portfolio gives mass Has huge opportunity to go global Big jump in US share in 2007 due to WH addition 36% 46% 52% 39% Europe North America Go Global Act Local

10 QIAGEN s Revenue Distribution By Customer Groups Life Sciences Major innovation initiatives Significant focus More resources than ever Molecular Diagnostics Applied Testing Applied Testing cador assay portfolio Forensic packages 11% 27% 8% 48% 27% 24% 17% Pharma Successes a lot of opportunities Molecular Diagnostics Critical mass - leading position Significant room to grow Pharmaceutical Industry Research Tailored Sales and Marketing Channels New Records in Innovation Products < 1 years old # of launched products 72 Revenue share ~4 % Revenues > $15 MM Products < 3 years old # of launched products 170 Revenue share (1) ~17 % Revenues > $75 MM Exceeded Innovation Targets. Again (1) Pre-merger QIAGEN for E&I, Jp, NA

11 New Records in Innovation QIAsymphony (SP Module)

12 QIAsymphony More than 400 man years 3 QIAGEN development sites Supported by 12 external development partners The first module in a revolutionary series QIAxcel

13 EZ1 Advanced 1 Billion Samples Extracted with QIAGEN Sample 1 Billion Sample Technology Products Sold

14 ~15 Million Diagnostic Tests Sold in 2007 ~15 MM Diagnostic Assays Sold in 2007 Mergers and Acquisitions (I)

15 Landmark Merger and Acquisitions (II) -34- Integration well on Track Resources FTE Plan Phase 4 HR, Budget 08, Going Direct Implement new business processes Transfer of projects to line Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Pre- Planing Pre- Closing Post- Closing Implementation Line functions take over all responsibilities Announcement Closing DAY 1 New Budget 2008 and Going direct TODAY Certain integration projects continue

16 Meeting Integration Milestones Project Up-date > 80 integration projects ongoing ~ 525 high level project milestones identified > 50% of milestones achieved Synergy targets Revenues: synergies accelerate 2009 Costs: ~ $35-45 million in 2008 Thereof COS 10% - 15% R&D 20% - 25% S&M 20% - 25% G&A 45% - 50% Our Goals 2008 Goals Classes for 2008 Financial Exceed/meet financial targets Strategic Increase strategic value: Standardization-Dissemination-Systems Biology Operational Operational Excellence - Processes - Organization Communication Increase clarity and awareness of our mission and value propositions HR Create employee base which excels in terms of talent and engagement Make QIAGEN an even better place to work Integration Together we are stronger: Fast integration, fast results for our customers and patients

17 Key: Synchronized Translation of Goals General Corporate General Goals EC - Functional 6 Major Goals ~ 200 Sub-goals Measurable Actionable On Intranet Global Organization Measure progress Delegate Manage Monitor Outlook 2008 Execution on strategy Standardization Dissemination Convergence Four customer segments for same core Innovation focus continues 2008 launches extremely important Launches delivering results Assay expansion, platform advancements Content expansion Integrations Globalization

18 Questions & Answers